Trials / Completed
CompletedNCT02074657
"LANK-2": Activated and Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy in Children, Adolescents and Young Adults With Relapsed or Refractary Acute Leukemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Hospital Universitario La Paz · Academic / Other
- Sex
- All
- Age
- 23 Years
- Healthy volunteers
- Not accepted
Summary
To determine safety profile of immunotherapy with natural killer cells and activated expanded (NKAEs) after salvage chemotherapy in children, adolescents and young adults with relapsed or refractary acute leukemia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Activated and expanded natural killer cells (NKAEs) | Activated and expanded natural killer cells (NKAEs) from haploidentical donor |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2016-09-01
- Completion
- 2016-09-01
- First posted
- 2014-02-28
- Last updated
- 2016-12-20
Locations
2 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT02074657. Inclusion in this directory is not an endorsement.